A new type of non -opioid analgesics for the purpose of treating short -term pain in adults is approved by the US Food and Drug Administration (FDA).
Narcotrotus, a nominal nomination, is working by targeting pain signals before reaching the brain.
Pharmaceuticals, a manufacturer, stated that it could effectively rescue the extremely severe pain from the “opioido poisoning potential”.
For many years, the United States has been working on analgesics and analgesic crises. In 2017, the US President called it “the shame of the people” and declared an emergency situation of public health.
FDA stated in clinical trials that JOUNAVX had reduced the pain after surgery and called its approval the “important public health milestone in acute pain management.”
According to the US Disease Prevention Center (CDC), tens of thousands of Americans have died of opioids due to the use of opioids, and in 2022 they have died of overdose of 82,000 opioid intake.
Now, in his second term, President Trump has it He said that 25 % of border taxes would reach imports from Canada and Mexico. Intercus to Japan to deal with a large amount of Fentanyl (powerful synthetic opioid).
The President threatened to impose tariffs on China, quoted for the export of the national Fentanil.
Opioid Work by stimulating the opioid receptor in the brain and blocking the signal of pain。
In the process, the brain is inundated in the neurotransmitter Dow pamin, creates emotions of euphoria, and activates the reward system of the brain.
As a result, opioids are addictive. The top is estimated that nearly 10 % of acute pain patients treated with opioids continue to extend the use of opioids.
However, JOURNAVX works in another way, By blocking the pain signal before reaching the brain.
According to Vertex, the drug is the first in new class pain medicine that has been approved for over 20 years.
The highest executive officer, RESHMA Kewalramani, called “80 million historical milestones in the United States, which prescribes severe acute pain drugs every year.”
Journavx costs $ 15.50 (£ 12.50) for each capsule. The company said, Additionally, it is not yet known whether the medicine is “safe and effective”.
